Recursion is eliminating approximately 20% of its workforce, in a restructuring that reflects challenges seen across the biopharma industry.

Nvidia’s forthright ambitions to expand its drug development footprint are ... stage assets across rare disease and oncology. Recursion's work has also drawn in partnerships with companies ...